Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare Diseases

News   Mar 16, 2018 | Original story from Louisiana State University

 
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare Diseases

Chemotherapeutic vandetanib bound to its main target, Protein Tyrosine Kinase 6, or PTK6, in purple, which is involved in many cancers including gastrointestinal tumors and ovarian cancers. By modeling vandetanib and PTK6 complex, researchers at LSU found the KRAS protein to also contain a similar drug-binding site and therefore to be a good match for the same drug. The computer-generated model of KRAS in gold with vandetanib depicts the predicted interaction. Credit: Misagh Naderi, LSU

 
 
 

RELATED ARTICLES

First Detailed Structure of Telomerase Revealed

News

Over 30 years after its discovery, the detailed molecular structure of the longevity protein telomerase has been revealed, which may have implications for cancer treatment and bone marrow transplants.

READ MORE

“Lymphoma Micro-reactor” Targets Chemo-Resistant Lymphoma

News

Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.

READ MORE

Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat Melanoma

News

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Informatics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE